Drew Moghanaki, Professor, Chief of Thoracic Oncology at David Geffen School of Medicine at UCLA, shared on LinkedIn:
“An important study from Shandong, China, by Xiaolong Wang et al., reinforces what has already been seen in locally advanced NSCLC: omitting the CTV reduces side effects and may actually improve overall survival in limited – stage small – cell lung cancer (LS-SCLC).
Their analyses also demonstrate a noticeable PFS benefit when omitting the CTV for pts also receiving immunotherapy.
Ref.”
Title: Efficacy and safety of omitting the clinical target volume in limited-stage small cell lung cancer: a large-scale multicenter real-world study
Authors: Xiaolong Wang, Xinrui Yu, Xiaoli Liu, Kaikai Zhao, Yankang Li, Hong Feng, Meili Sun, Jinming Yu, Yu Chen, Xiangjiao Men
Other articles featuring Drew Moghanaki on OncoDaily.
